Mebutamate

DB06797

small molecule approved

Deskripsi

Mebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a sedative. Side effects include dizziness and headaches.

Struktur Molekul 2D

Berat 232.2768
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

663 Data
Buprenorphine Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mebutamate.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Mebutamate.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Mebutamate.
Hydrocodone Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mebutamate.
Magnesium sulfate The therapeutic efficacy of Mebutamate can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Mebutamate may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mebutamate.
Mirtazapine Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Mebutamate.
Orphenadrine Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Mebutamate.
Pramipexole Mebutamate may increase the sedative activities of Pramipexole.
Ropinirole Mebutamate may increase the sedative activities of Ropinirole.
Rotigotine Mebutamate may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Mebutamate.
Sodium oxybate Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Mebutamate.
Thalidomide Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Yohimbine The therapeutic efficacy of Mebutamate can be increased when used in combination with Yohimbine.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Mebutamate.
Ethanol Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Mebutamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Mebutamate.
Fluvoxamine The risk or severity of adverse effects can be increased when Mebutamate is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Mebutamate is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Mebutamate is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Mebutamate is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Mebutamate is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Mebutamate is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Mebutamate is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Mebutamate is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Mebutamate is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Mebutamate is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Mebutamate is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Mebutamate is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Mebutamate is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Mebutamate is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Mebutamate is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Mebutamate is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Mebutamate is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Mebutamate.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Mebutamate.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Mebutamate.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Mebutamate.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Mebutamate.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Mebutamate.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Mebutamate.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Mebutamate.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Mebutamate.
Pizotifen The risk or severity of CNS depression can be increased when Pizotifen is combined with Mebutamate.
Dosulepin The risk or severity of CNS depression can be increased when Mebutamate is combined with Dosulepin.
Zopiclone The risk or severity of adverse effects can be increased when Mebutamate is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Mebutamate.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Mebutamate.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Mebutamate.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Mebutamate.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Mebutamate.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Mebutamate.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Mebutamate.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Mebutamate.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Mebutamate.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Mebutamate.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Mebutamate.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Mebutamate.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Mebutamate.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Mebutamate.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Mebutamate.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Mebutamate.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Mebutamate.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Mebutamate.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Mebutamate.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Mebutamate.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Mebutamate.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Mebutamate.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Mebutamate.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Mebutamate.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Mebutamate.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Mebutamate.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Mebutamate.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Mebutamate.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Mebutamate.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Mebutamate.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Mebutamate.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Mebutamate.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Mebutamate.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Mebutamate.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Mebutamate.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Mebutamate.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Mebutamate.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Mebutamate.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Mebutamate.
Palonosetron The risk or severity of CNS depression can be increased when Palonosetron is combined with Mebutamate.
Sulpiride The risk or severity of CNS depression can be increased when Sulpiride is combined with Mebutamate.
Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Mebutamate.

Target Protein

Gamma-aminobutyric acid receptor subunit gamma-3 GABRG3

Referensi & Sumber

Synthesis reference: U.S. Patent 2,878,280.
Artikel (PubMed)
  • PMID: 6037393
    Tetreault L, Richer P, Bordeleau JM: Hypnotic properties of mebutamate: a comparative study of mebutamate, secobarbital and placebo in psychiatric patients. Can Med Assoc J. 1967 Aug 19;97(8):395-8.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Dormate — Medpointe Pharm HLC

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul